- ￥1050 - 4000
- MedChemExpress(MCE)
- 美国
- HY-133123
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
2287259-07-6
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥2521.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥1050.0 |
| 规格： | 5 mg | 产品价格： | ￥2500.0 |
| 规格： | 10 mg | 产品价格： | ￥4000.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
EP4 receptor antagonist 1
CAS No. : 2287259-07-6
MCE 国际站：EP4 receptor antagonist 1
产品活性：EP4 receptor antagonist 1 是一种高效的，竞争性的，选择性前列腺素类 EP4 受体拮抗剂。可用于癌症免疫研究。EP4 receptor antagonist 1 抑制人和小鼠 EP4 受体，IC50 分别为 6.1 nM 和 16.2 nM。对人 EP1，EP2 和 EP3 受体的 IC50 >10 μM。
研究领域：GPCR/G Protein
作用靶点：Prostaglandin Receptor
In Vitro: The antagonistic effect of EP4 receptor antagonist 1 (Compounds 59) on human EP4 in calcium flux assay with an IC50 of 6.1±0.2 nM in CHO-Gα16 cells overexpressing human EP4 receptor. The antagonistic effect of EP4 receptor antagonist 1 on human EP4 in calcium flux assay with an IC50 of 16.2±1.7 nM in CHO-Gα16 cells overexpressing mouse EP4 receptor.
EP4 receptor antagonist 1 dose dependently inhibits PGE2-stimulated cAMP accumulation in HEK293-EP4 cells with an IC50 of 18.7±0.6 nM. EP4 receptor antagonist 1 dose-dependently inhibits the activity of the CRE reporter in HEK293 cells with an IC50 of 5.2±0.4 nM.EP4 receptor antagonist 1 dose-dependently inhibits PGE2-stimulated β-arrestin recruitment in HEK293-EP4 cells with an IC50 of 0.4±0.1 nM.
EP4 receptor antagonist 1 (1 nM-10 μM) reverses PGE2-induced ERK phosphorylation in a concentration-dependent manner.
In Vivo: EP4 receptor antagonist 1 (16, 50, and 150 mg/kg; orally; once daily for two weeks) causes significant inhibition of tumor growth in BALB/c female mice. No significant body weight loss is found in any mouse cohorts. EP4 receptor antagonist 1 is well tolerated in mice at the tested dosage.
EP4 receptor antagonist 1 (1 mg/kg; intravenously) demonstrates moderate clearance (CL=1.7 L/h/kg) in mice with a corresponding favorable half-life (t1/2) of 4.1 h. EP4 receptor antagonist 1 (5 mg/kg; orally) exhibits good bioavailability (F=48.0%) in mice with a corresponding favorable half-life (t1/2) of 4.7 h.
相关产品：Prostaglandin E2 | EIPA | Prostaglandin E1 | Tranilast | PF-04418948 | U-46619 | Iloprost | Prostaglandin D2 | ONO-AE3-208 | Dinoprost | Palupiprant | Latanoprost | Selexipag | 16,16-Dimethyl prostaglandin E2 | Treprostinil | DG-041 | Grapiprant | L-798106 | GW627368 | Fevipiprant | Asapiprant | AH 6809 | L-161982 | Laropiprant | Bimatoprost | CJ-42794 | MF498 | Beraprost sodium | Ramatroban
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Chemokine Receptor Antagonist Development
This chapter describes assays that focus on the characterization of compounds identified in high-�throughput screening campaigns, and the subsequent medicinal chemistry programs. They cover methods to determine potency
Developing a Photoreactive Antagonist
approach for developing small molecules that, upon irradiation with light, may be used to rapidly inactivate targeted proteins expressed on the surfaces of cells. Highlighted is ANQX, a photoreactive AMPA receptor antagonist developed to irreversibly
Prasugrel: A Novel Platelet ADP P2Y12 Receptor Antagonist
than clopidogrel without an unacceptable increase in hemorrhagic or other side effects. Prasugrel (CS-747; LY-640315), a novel third-generation oral thienopyridine, is a specific, irreversible antagonist of the platelet ADP P2Y12 receptor. Pre-clinical and early
技术资料暂无技术资料 索取技术资料
